investment analyst coverage

In a survey, analysts found that reimbursement and test awareness were major barriers to driving adoption of the firm's assay for identifying skin cancer.

Both firms highlighted 908's Rebel miniature mass spectrometry system, which is used in bioprocess work, as key to the company's fortunes.

Despite the havoc wreaked by the COVID-19 pandemic on the economy, several companies in the index saw their shares rise by triple-digit percentages last year.

Cowen highlighted the company's potential for allowing proteomics experiments at scale, allowing for deep proteomic measurements at high throughput.

The investment bank highlighted the technology underlying DermTech's non-invasive, skin patch-based melanoma test as key to its future growth.

BTIG highlighted the firm's cancer test portfolio, as well as its growing position in the liquid biopsy and minimal residual disease testing space.

The index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all swung up on positive coronavirus vaccine news.

The investment bank sees the potential for strong revenue growth over time as Oncocyte expands its product portfolio and launches new tests.

William Blair, Canaccord Genuity, and BTIG on Monday initiated coverage of newly public Biodesix, with ratings ranging from Buy to Outperform.